Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
CBST [NASD]
Cubist Pharmaceuticals Inc.
Index- P/E3457.50 EPS (ttm)0.02 Insider Own0.40% Shs Outstand75.73M Perf Week11.55%
Market Cap5.24B Forward P/E43.96 EPS next Y1.57 Insider Trans12.23% Shs Float75.36M Perf Month5.44%
Income8.40M PEG172.88 EPS next Q0.03 Inst Own- Short Float7.23% Perf Quarter10.38%
Sales1.12B P/S4.67 EPS this Y-112.90% Inst Trans-0.34% Short Ratio7.34 Perf Half Y3.97%
Book/sh19.73 P/B3.50 EPS next Y125.68% ROA0.30% Target Price82.69 Perf Year4.47%
Cash/sh8.50 P/C8.14 EPS next 5Y20.00% ROE0.60% 52W Range58.50 - 82.12 Perf YTD0.41%
Dividend- P/FCF166.77 EPS past 5Y-16.30% ROI2.30% 52W High-12.83% Beta0.69
Dividend %- Quick Ratio2.60 Sales past 5Y19.40% Gross Margin72.90% 52W Low22.36% ATR2.39
Employees873 Current Ratio2.80 Sales Q/Q13.80% Oper. Margin12.90% RSI (14)64.72 Volatility4.12% 3.80%
OptionableYes Debt/Eq0.60 EPS Q/Q30.40% Profit Margin0.70% Rel Volume1.20 Prev Close69.15
ShortableYes LT Debt/Eq0.56 EarningsOct 21 AMC Payout0.00% Avg Volume742.32K Price71.58
Recom2.20 SMA2010.02% SMA508.27% SMA2003.72% Volume566,681 Change3.51%
20-Jun-14Initiated Gabelli & Co Buy
12-Mar-14Reiterated Mizuho Buy $81 → $97
06-Mar-14Reiterated UBS Buy $75 → $90
24-Jan-14Reiterated Mizuho Buy $77 → $81
24-Jan-14Reiterated Aegis Capital Buy $70 → $85
20-Dec-13Reiterated RBC Capital Mkts Outperform $78 → $82
10-Oct-13Initiated Oppenheimer Outperform $81
09-Oct-13Upgrade Mizuho Neutral → Buy $50 → $77
01-Aug-13Upgrade Aegis Capital Hold → Buy $56 → $70
31-Jul-13Reiterated UBS Buy $61 → $70
21-May-13Upgrade Cantor Fitzgerald Sell → Hold $40 → $49
21-May-13Reiterated RBC Capital Mkts Outperform $53 → $63
03-May-13Initiated UBS Buy $61
03-Apr-13Downgrade Cantor Fitzgerald Hold → Sell $38 → $40
06-Feb-13Initiated Aegis Capital Hold $45
24-Jan-13Upgrade Cantor Fitzgerald Sell → Hold $37 → $38
04-Jan-13Resumed Robert W. Baird Neutral $46
09-Nov-12Initiated Mizuho Neutral $44
25-Oct-12Initiated Cantor Fitzgerald Sell $37
04-Apr-12Reiterated Oppenheimer Outperform $45 → $49
23-Oct-14 09:00AM  Cubist Pharmaceuticals' Q3 Earnings Beat Expectations Zacks
22-Oct-14 05:18PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:08PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
02:30PM  Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's "Storm The Castle" Stock at TheStreet
21-Oct-14 04:29PM  Cubist beats Street 3Q forecasts AP
04:11PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online
04:00PM  Cubist Reports Third Quarter 2014 Financial Results Business Wire
07:07AM  Q3 2014 Cubist Pharmaceuticals Inc Earnings Release - 4:00 pm ET CCBN
20-Oct-14 04:58PM  Bank Of America Q3 Small & Mid-Cap Biotech Preview Benzinga
07:30AM  Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer Business Wire
14-Oct-14 09:00AM  Cubist to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014 Business Wire
08-Oct-14 08:30AM  Cubist to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014 Business Wire
06-Oct-14 10:58AM  Actavis Expands Antibiotics Presence With Durata Buy at Investor's Business Daily
30-Sep-14 08:30AM  Cubist to Present New Data on Antibiotics Portfolio at IDWeek 2014 Business Wire
18-Sep-14 05:29PM  White House calls for task force to tackle antibiotic-resistant bugs Reuters
04:30AM  Cubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich Business Wire
26-Aug-14 08:30AM  Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Business Wire
25-Aug-14 05:25PM  Cubist Pharmaceuticals' Antibiotic Accepted for EU Review Zacks
09:00AM  Cubist to Present at Morgan Stanley Global Healthcare Conference Business Wire
22-Aug-14 07:30AM  Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review Business Wire
18-Aug-14 12:37PM  Cubist Pharmaceuticals (CBST) Marked As A Barbarian At The Gate at TheStreet
09:39AM  Cubist Battling Superbugs Offers Remedy for J&J: Real M&A at Bloomberg
17-Aug-14 04:00AM  Extreme medicine: The search for new antibiotics Reuters
15-Aug-14 01:04PM  CUBIST PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 08:07AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
08:06AM  CUBIST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08-Aug-14 05:47PM  Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Following Complaints of Foreign Particulate Matter in Reconstituted Vials Business Wire
07-Aug-14 11:44AM  Is Durata's Antibiotic Overpriced? A Twitter Conversation at Forbes
06-Aug-14 04:13PM  Cubist recalls antibiotic over possible glass AP
08:42AM  Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter Business Wire
08:24AM  Cubist Pharma recalls some vials of antibiotic Cubicin Reuters
08:18AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
06:00AM  The R&D elite: America's most innovative companies at CNBC
05-Aug-14 08:30AM  Cubists Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations Business Wire
28-Jul-14 09:00AM  Cubist to Present at August Investor Conference Business Wire
23-Jul-14 12:10PM  Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Zacks
22-Jul-14 04:11PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online
04:00PM  Cubist Reports Second Quarter 2014 Financial Results Business Wire
07:17AM  Zacks Rank #5 Additions for Tuesday Zacks
07:07AM  Q2 2014 Cubist Pharmaceuticals, Inc. Earnings Release - 4:00 pm ET CCBN
20-Jul-14 09:11AM  Top Biotech Earnings Previews for the Week Ahead at 24/7 Wall St.
19-Jul-14 03:02PM  Investing to Fight Toilet and Elevator Superbugs at Motley Fool
15-Jul-14 09:00AM  Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014 Business Wire
14-Jul-14 04:01PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
11-Jul-14 08:16AM  If Big Pharma Ignores Antibacterial R&D, Where Will We Get The Drugs To Treat Superbugs? at Forbes
28-Jun-14 05:01PM  3 Biotech Stocks with Jaw-Dropping Growth Potential at Motley Fool
24-Jun-14 01:06AM  Cubist and Durata Heat Up Antibiotic Market at Motley Fool
23-Jun-14 03:38PM  [video] Cubist advances Sivextro at CNBC
12:24PM  Cubist Pharmaceuticals (CBST) Is Water-Logged And Getting Wetter Today at TheStreet
10:50AM  Cubist Gains FDA Approval for Sivextro Zacks
09:23AM  Will This Price Target Increase Help Cubist Pharmaceuticals (CBST) Stock Today? at TheStreet
08:41AM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:23AM  Cubist Sivextro sales to benefit from lack of warnings, says JMP Securities at theflyonthewall.com
20-Jun-14 09:35PM  F.D.A. Approves Antibiotic for Common Infections at New York Times +5.38%
06:42PM  Antibiotic Pipeline Revival: FDA Approves Cubist Pharmaceuticals' SIVEXTRO For MRSA, Other Serious Skin Infections at Forbes
06:32PM  FDA approves Cubist antibiotic for skin infections AP
06:00PM  Cubists SIVEXTRO (tedizolid phosphate) Approved in U.S. to Treat Serious Skin InfectionsIncluding Those Caused by MRSA Business Wire
05:58PM  Cubist receives FDA approval for MRSA antibiotic Sivextro at theflyonthewall.com
05:56PM  Cubist Wins U.S. Approval for MRSA Antibiotic Sivextro at Bloomberg
10:00AM  Cubist Gets Priority Review from FDA for Antibiotic Candidate Zacks
09:10AM  Coverage initiated on Cubist Pharma by Gabelli & Co Briefing.com
19-Jun-14 06:22PM  On The Fly: After Hours Movers at theflyonthewall.com
05:23PM  Cubist Readies For Takeoff With New Antibiotic Launch at Investor's Business Daily
04:30PM  Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review Business Wire
16-Jun-14 05:00PM  Must-know: Why Maverick Capital disposes position in Zoetis Market Realist
13-Jun-14 05:00PM  Why Maverick opens new position in Cubist Pharmaceuticals Market Realist
02:46PM  [$$] Two Undervalued Biopharmas to Buy Now at Barrons.com
12-Jun-14 02:30PM  FDA panel advises against large opioid constipation drug safety trials Reuters
12:57PM  Panel does not back CV safety trials for OIC drugs, Reuters says at theflyonthewall.com
12:34PM  FDA panel advises against large opioid-constipation drug trials Reuters
10-Jun-14 03:30PM  Cubist Pharma's Antibiotics Portfolio Holds Promise Zacks
06-Jun-14 09:00AM  Cubist Announces Publication of Pivotal Data from SIVEXTRO (tedizolid phosphate) ESTABLISH-2 Clinical Trial in The Lancet Infectious Diseases Business Wire
04-Jun-14 04:01PM  CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
02-Jun-14 09:34AM  Cubist to Present at June Investor Conferences Business Wire
27-May-14 06:32PM  2 Growth Stocks You Need to Know About at Motley Fool
23-May-14 04:05PM  U.S. FDA approves Durata's acute bacterial skin infection drug Reuters
13-May-14 09:01AM  Cubist gram-negative antibiotic data supports approval, says JMP Securities at theflyonthewall.com
11-May-14 02:25PM  Cubist presents results from Phase 3 trials of ceftolozane/tazobactam at theflyonthewall.com
09-May-14 07:01PM  Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Business Wire
03:03PM  [$$] Antibiotics Approvals to Surge at Barrons.com
07-May-14 07:21AM  CBS Earnings Preview: Falling Expectations? Benzinga
05-May-14 06:32PM  3 Biotech Stocks Making Big Moves Last Week at Motley Fool
03-May-14 12:15PM  Why We're Running Out Of Antibiotics Is An Economic Problem, Not A Medical Or Pharmaceutical One at Forbes
02-May-14 08:30AM  CUBIST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:25AM  Biotechnology Capital Inflows Reach Historic Highs: A Wall Street Transcript Interview with Brian Skorney, a Senior Analyst with Robert W. Baird & Co. Covering Biotechnology Wall Street Transcript
30-Apr-14 10:07AM  Cubist to Present New Antibiotics Pipeline Data at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Business Wire
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VINK PATRICK V.J.J.SVP & GM, International Bus.Oct 15Option Exercise0.002,12505,496Oct 16 04:00 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerOct 01Option Exercise65.3948,1253,146,71175,723Oct 02 04:07 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerOct 01Sale65.3948,1253,146,71027,598Oct 02 04:07 PM
STEA GREGORYSVP, Commercial OperationsAug 19Option Exercise37.3838,3261,432,79856,462Aug 20 04:11 PM
STEA GREGORYSVP, Commercial OperationsAug 19Sale65.8838,3262,524,85218,136Aug 20 04:11 PM
Hutson Nancy JDirectorAug 18Option Exercise0.009,000014,951Aug 18 04:06 PM
Hutson Nancy JDirectorAug 18Sale65.009,000585,0005,951Aug 18 04:06 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerAug 18Sale63.6840926,0436,132Aug 18 04:03 PM
PEREZ ROBERT JPresident & COOAug 18Sale63.681,00363,86647,325Aug 18 04:05 PM
PEREZ ROBERT JPresident & COOAug 15Option Exercise0.002,125048,328Aug 18 04:05 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerAug 15Option Exercise0.001,25006,541Aug 18 04:03 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJul 28Option Exercise25.2340,6251,024,96968,223Jul 29 04:01 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJul 28Sale61.5740,6252,501,10427,598Jul 29 04:01 PM
MOULDER LEON O JRDirectorJun 03Option Exercise0.001,104011,101Jun 05 03:11 PM
Soeters Martinus HermanusDirectorJun 03Option Exercise0.001,104010,397Jun 05 03:12 PM
Lawton Alison FrancesDirectorJun 03Option Exercise0.001,10404,717Jun 05 03:09 PM
HENNEY JANE E MDDirectorJun 03Option Exercise0.001,10404,644Jun 05 03:08 PM
CORRIGAN MARKDirectorJun 03Option Exercise0.001,10407,501Jun 05 03:07 PM
BATE KENNETHDirectorJun 03Option Exercise0.001,70109,615Jun 05 03:06 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 15Option Exercise16.7615,125253,49542,723May 15 02:43 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 15Sale67.8216,3401,108,24027,598May 15 02:43 PM
BONNEY MICHAEL WChief Executive OfficerMay 15Sale67.503,036204,930175,859May 15 02:42 PM
PEREZ ROBERT JPresident & COOMay 15Sale67.501,518102,46545,869May 15 02:44 PM
STEA GREGORYSVP, Commercial OperationsMay 15Sale67.5087559,06318,136May 15 02:46 PM
STEA GREGORYSVP, Commercial OperationsMay 14Option Exercise0.001,800019,011May 15 02:46 PM
PEREZ ROBERT JPresident & COOMay 14Option Exercise0.003,125047,387May 15 02:44 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 14Option Exercise0.002,500028,813May 15 02:43 PM
BONNEY MICHAEL WChief Executive OfficerMay 14Option Exercise0.006,2500178,895May 15 02:42 PM
STEA GREGORYSVP, Commercial OperationsMay 14Sale69.0086559,68517,211May 14 04:13 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerMay 14Sale69.0049934,4315,291May 14 04:13 PM
BONNEY MICHAEL WChief Executive OfficerMay 14Sale69.003,840264,960172,645May 14 04:10 PM
PEREZ ROBERT JPresident & COOMay 14Sale69.002,400165,60044,262May 14 04:12 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 14Sale69.001,680115,92026,313May 14 04:11 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerMay 13Option Exercise0.003,500027,993May 14 04:11 PM
PEREZ ROBERT JPresident & COOMay 13Option Exercise0.005,000046,662May 14 04:12 PM
BONNEY MICHAEL WChief Executive OfficerMay 13Option Exercise0.008,0000176,485May 14 04:10 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerMay 13Option Exercise0.001,50005,790May 14 04:13 PM
STEA GREGORYSVP, Commercial OperationsMay 13Option Exercise0.001,800018,076May 14 04:13 PM
DesRosier ThomasEVP, Chief LegalApr 16Sale64.0076849,1521,609Apr 16 04:44 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerApr 16Sale64.0044128,2244,290Apr 16 04:45 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerApr 15Option Exercise0.001,36104,731Apr 16 04:45 PM
DesRosier ThomasEVP, Chief LegalApr 15Option Exercise0.002,37702,377Apr 16 04:44 PM
STEA GREGORYSVP, Commercial OperationsMar 06Option Exercise42.094,600193,61420,876Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 06Sale79.994,600367,95416,276Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 05Option Exercise36.7515,289561,92828,665Mar 06 04:38 PM
STEA GREGORYSVP, Commercial OperationsMar 05Sale79.6715,2891,218,03916,276Mar 06 04:38 PM
CORRIGAN MARKDirectorFeb 27Option Exercise18.225,00091,10010,498Feb 28 02:06 PM
PEREZ ROBERT JPresident & COOFeb 27Option Exercise19.5130,000585,30071,662Feb 28 04:04 PM
BONNEY MICHAEL WChief Executive OfficerFeb 27Option Exercise10.84100,0001,084,000268,485Feb 28 04:06 PM
PEREZ ROBERT JPresident & COOFeb 27Sale80.1830,0002,405,43941,662Feb 28 04:04 PM
CORRIGAN MARKDirectorFeb 27Sale80.005,000400,0005,498Feb 28 02:06 PM
BONNEY MICHAEL WChief Executive OfficerFeb 27Sale81.25100,0008,125,130168,485Feb 28 04:06 PM
BONNEY MICHAEL WChief Executive OfficerFeb 20Sale75.603,112235,268168,485Feb 21 08:06 AM
BONNEY MICHAEL WChief Executive OfficerFeb 19Option Exercise0.009,5000171,597Feb 21 08:06 AM
STEA GREGORYSVP, Commercial OperationsFeb 18Sale75.0098573,87516,276Feb 19 03:40 PM
PEREZ ROBERT JPresident & COOFeb 18Sale75.003,504262,80041,662Feb 19 03:39 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 18Sale75.002,645198,37524,493Feb 19 03:37 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 18Sale75.0055541,6253,370Feb 19 03:36 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 16Option Exercise0.0083303,925Feb 19 03:36 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 16Option Exercise0.003,750027,138Feb 19 03:37 PM
PEREZ ROBERT JPresident & COOFeb 16Option Exercise0.005,000045,166Feb 19 03:39 PM
STEA GREGORYSVP, Commercial OperationsFeb 16Option Exercise0.001,600017,261Feb 19 03:40 PM
STEA GREGORYSVP, Commercial OperationsFeb 15Option Exercise0.001,472015,661Feb 19 03:40 PM
PEREZ ROBERT JPresident & COOFeb 15Option Exercise0.002,554040,166Feb 19 03:39 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerFeb 15Option Exercise0.001,953023,388Feb 19 03:37 PM
TOMSICEK MICHAEL JOHNSVP & Chief Financial OfficerFeb 15Option Exercise0.0075103,092Feb 19 03:36 PM
VINK PATRICK V.J.J.SVP & GM, International Bus.Feb 15Option Exercise0.001,24603,371Feb 19 03:35 PM
BATE KENNETHDirectorFeb 03Option Exercise22.716,250141,93814,164Feb 04 12:22 PM
BATE KENNETHDirectorFeb 03Sale72.156,250450,9527,914Feb 04 12:22 PM
PEREZ ROBERT JPresident & COOJan 15Option Exercise22.1410,000221,40047,612Jan 15 03:10 PM
STEA GREGORYSVP, Commercial OperationsJan 15Option Exercise34.805,312184,83119,501Jan 15 03:12 PM
PEREZ ROBERT JPresident & COOJan 15Sale74.9510,000749,50037,612Jan 15 03:10 PM
STEA GREGORYSVP, Commercial OperationsJan 15Sale74.905,312397,86914,189Jan 15 03:12 PM
PEREZ ROBERT JPresident & COOJan 13Option Exercise22.1410,000221,40047,612Jan 14 03:56 PM
PEREZ ROBERT JPresident & COOJan 13Sale72.9510,000729,50037,612Jan 14 03:56 PM
BATE KENNETHDirectorJan 09Option Exercise9.5610,00095,60017,914Jan 09 04:58 PM
BATE KENNETHDirectorJan 09Sale70.0010,000700,0007,914Jan 09 04:58 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJan 02Option Exercise18.6925,000467,25048,540Jan 02 03:15 PM
GILMAN STEVEN CEVP & Chief Scientific OfficerJan 02Sale67.8225,0001,695,44323,540Jan 02 03:15 PM
BATE KENNETHDirectorDec 02Option Exercise10.0912,500126,12520,414Dec 03 04:07 PM
BATE KENNETHDirectorDec 02Sale67.6312,500845,3687,914Dec 03 04:07 PM
PEREZ ROBERT JPresident & COONov 25Option Exercise21.6140,000864,40057,536Nov 27 08:33 AM
STEA GREGORYSVP, Commercial OperationsNov 25Option Exercise33.1622,812756,52727,001Nov 27 08:34 AM
STEA GREGORYSVP, Commercial OperationsNov 25Sale69.3022,8121,580,84914,189Nov 27 08:34 AM
PEREZ ROBERT JPresident & COONov 25Sale69.3440,0002,773,51337,536Nov 27 08:33 AM